{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:58:28Z","timestamp":1794045508034,"version":"4.8.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/qai.0b013e3181bca669","type":"journal-article","created":{"date-parts":[[2009,10,21]],"date-time":"2009-10-21T03:16:22Z","timestamp":1256094982000},"page":"309-315","source":"Crossref","is-referenced-by-count":84,"title":["Minority Variants Associated with Transmitted and Acquired HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance: Implications for the Use of Second-Generation Nonnucleoside Reverse Transcriptase Inhibitors"],"prefix":"10.1097","volume":"52","author":[{"given":"Vici","family":"Varghese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajin","family":"Shahriar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Yon","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte B","family":"Simen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Egholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bozena","family":"Hanczaruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth A","family":"Blake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baback","family":"Gharizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farbod","family":"Babrzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Jeffrey","family":"Fessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-2-20210131","first-page":"107","article-title":"2004:which HIV-1 drug resistance mutations are common in clinical practice?","volume":"6","author":"Cheung","year":"2004","journal-title":"AIDS Rev"},{"key":"R3-2-20210131","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1128\/AAC.48.8.3122-3126.2004","article-title":"Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing.","volume":"48","author":"Rhee","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-2-20210131","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1086\/432916","article-title":"Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.","volume":"192","author":"Wensing","year":"2005","journal-title":"J Infect Dis"},{"key":"R6-2-20210131","doi-asserted-by":"crossref","first-page":"12773","DOI":"10.1128\/JVI.79.20.12773-12782.2005","article-title":"TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.","volume":"79","author":"Vingerhoets","year":"2005","journal-title":"J Virol"},{"key":"R7-2-20210131","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1128\/JVI.75.11.4999-5008.2001","article-title":"Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.","volume":"75","author":"Bacheler","year":"2001","journal-title":"J Virol"},{"key":"R8-2-20210131","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1086\/323153","article-title":"Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).","volume":"184","author":"Eshleman","year":"2001","journal-title":"J Infect Dis"},{"key":"R9-2-20210131","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1089\/aid.2007.0045","article-title":"Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.","volume":"23","author":"Kassaye","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R10-2-20210131","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1128\/JCM.39.4.1522-1529.2001","article-title":"High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.","volume":"39","author":"Shafer","year":"2001","journal-title":"J Clin Microbiol"},{"key":"R13-2-20210131","first-page":"67","article-title":"HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.","volume":"10","author":"Shafer","year":"2008","journal-title":"AIDS Rev"},{"key":"R14-2-20210131","doi-asserted-by":"crossref","first-page":"10747","DOI":"10.1128\/JVI.01827-07","article-title":"Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations.","volume":"82","author":"Mitsuya","year":"2008","journal-title":"J Virol"},{"key":"R15-2-20210131","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1086\/597808","article-title":"Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.","volume":"199","author":"Margeridon-Thermet","year":"2009","journal-title":"J Infect Dis"},{"key":"R16-2-20210131","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1086\/420789","article-title":"The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities.","volume":"189","author":"Weinstock","year":"2004","journal-title":"J Infect Dis"},{"key":"R18-2-20210131","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/135965350400900514","article-title":"Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe.","volume":"9","author":"Pillay","year":"2004","journal-title":"Antivir Ther"},{"key":"R19-2-20210131","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/QCO.0b013e328013caff","article-title":"Epidemiology of antiretroviral drug resistance in drug-naive persons.","volume":"20","author":"Geretti","year":"2007","journal-title":"Curr Opin Infect Dis"},{"key":"R20-2-20210131","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa041305","article-title":"Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.","volume":"351","author":"Jourdain","year":"2004","journal-title":"N Engl J Med"},{"key":"R21-2-20210131","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00126334-200501010-00007","article-title":"Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.","volume":"38","author":"Lecossier","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R22-2-20210131","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1371\/journal.pmed.0050158","article-title":"Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy.","volume":"5","author":"Johnson","year":"2008","journal-title":"PLoS Med"},{"key":"R23-2-20210131","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1086\/596736","article-title":"Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.","volume":"199","author":"Simen","year":"2009","journal-title":"J Infect Dis"},{"key":"R25-2-20210131","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.","volume":"105","author":"Keele","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R26-2-20210131","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1097\/00002030-200110190-00006","article-title":"Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).","volume":"15","author":"Eshleman","year":"2001","journal-title":"AIDS"},{"key":"R27-2-20210131","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1128\/AAC.44.9.2475-2484.2000","article-title":"Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.","volume":"44","author":"Bacheler","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-2-20210131","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00126334-200003010-00002","article-title":"Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response.","volume":"23","author":"Shulman","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R29-2-20210131","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1089\/08892220260139503","article-title":"Extent and importance of cross-resistance to efavirenz after nevirapine failure.","volume":"18","author":"Casado","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R30-2-20210131","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1468-1293.2008.00644.x","article-title":"Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.","volume":"9","author":"Ruxrungtham","year":"2008","journal-title":"HIV Med"},{"key":"R31-2-20210131","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/01.qai.0000214805.52723.c1","article-title":"Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing.","volume":"41","author":"Oette","year":"2006","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-200911010-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:04:13Z","timestamp":1786039453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-200911010-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181bca669","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}